Literature DB >> 2065891

Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development.

J Goudsmit1, N K Back, P L Nara.   

Abstract

Recent analysis of primate lentivirus genomes indicates that lentiviruses have infected primates for hundreds of years. The pathogenicity of such viruses may fluctuate due to the high evolution rate of some parts of the viral genome. Fixed nucleic acid substitutions in the gag gene appear to be caused by random fixation of selectively neutral mutants, whereas nonrandom fixation of selectively advantageous mutants, as has been observed for MHC molecules and serine protease inhibitors, appears to be operational for some hypervariable env gene regions. The former is characterized by an excess of silent mutations independent of the rate of change, the latter by an excess of nonsilent mutations. This latter type of selection may especially characterize the third variable region of the external HIV envelope (V3), which contains the principal neutralization domain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065891     DOI: 10.1096/fasebj.5.10.2065891

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition.

Authors:  M H Fernandez; A Faith; J A Higgins; J Weber; A D Rees
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

2.  Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function.

Authors:  R A McDonald; D L Mayers; R C Chung; K F Wagner; S Ratto-Kim; D L Birx; N L Michael
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  Heterogeneity of Neuropsychological Impairment in HIV Infection: Contributions from Mild Cognitive Impairment.

Authors:  Kathryn N Devlin; Tania Giovannetti
Journal:  Neuropsychol Rev       Date:  2017-05-24       Impact factor: 7.444

4.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.

Authors:  J M Rini; R L Stanfield; E A Stura; P A Salinas; A T Profy; I A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Towards the rational design of a candidate vaccine against pregnancy associated malaria: conserved sequences of the DBL6epsilon domain of VAR2CSA.

Authors:  Cyril Badaut; Gwladys Bertin; Tatiana Rustico; Nadine Fievet; Achille Massougbodji; Alioune Gaye; Philippe Deloron
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

9.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

Authors:  C F Barbas; E Björling; F Chiodi; N Dunlop; D Cababa; T M Jones; S L Zebedee; M A Persson; P L Nara; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability.

Authors:  L Milich; B Margolin; R Swanstrom
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.